EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 22022D1569
Decision of the EEA Joint Committee No 125/2022 of 29 April 2022 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2022/1569]
Decision of the EEA Joint Committee No 125/2022 of 29 April 2022 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2022/1569]
Decision of the EEA Joint Committee No 125/2022 of 29 April 2022 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2022/1569]
OJ L 246, 22.9.2022, p. 69–70
(BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
Date of entry into force unknown (pending notification) or not yet in force.
|
22.9.2022 |
EN |
Official Journal of the European Union |
L 246/69 |
DECISION OF THE EEA JOINT COMMITTEE No 125/2022
of 29 April 2022
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2022/1569]
THE EEA JOINT COMMITTEE,
Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,
Whereas:
|
(1) |
Commission Implementing Decision (EU) 2021/2149 of 3 December 2021 on unresolved objections regarding the terms and conditions of the provisional authorisation of a biocidal product containing 5-Chloro-2-methyl-2H-isothiazol-3-one (C(M)IT) referred by France in accordance with Article 36(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council (1) is to be incorporated into the EEA Agreement. |
|
(2) |
Commission Implementing Decision (EU) 2021/2174 of 3 December 2021 on unresolved objections regarding the terms and conditions of the authorisation of the biocidal product Konservan P40 in accordance with Article 36(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council (2) is to be incorporated into the EEA Agreement. |
|
(3) |
Annex II to the EEA Agreement should therefore be amended accordingly, |
HAS ADOPTED THIS DECISION:
Article 1
The following points are inserted after point 12zzzzzzzr (Commission Implementing Decision (EU) 2021/2148) of Annex II to the EEA Agreement:
|
‘12zzzzzzzs. |
32021 D 2149: Commission Implementing Decision (EU) 2021/2149 of 3 December 2021 on unresolved objections regarding the terms and conditions of the provisional authorisation of a biocidal product containing 5-Chloro-2-methyl-2H-isothiazol-3-one (C(M)IT) referred by France in accordance with Article 36(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 434, 6.12.2021, p. 5). |
|
12zzzzzzzt. |
32021 D 2174: Commission Implementing Decision (EU) 2021/2174 of 3 December 2021 on unresolved objections regarding the terms and conditions of the authorisation of the biocidal product Konservan P40 in accordance with Article 36(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 441, 9.12.2021, p. 1).’ |
Article 2
The texts of Implementing Decisions (EU) 2021/2149 and (EU) 2021/2174 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.
Article 3
This Decision shall enter into force on 30 April 2022, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*).
Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.
Done at Brussels, 29 April 2022.
For the EEA Joint Committee
The President
Nicolas VON LINGEN
(1) OJ L 434, 6.12.2021, p. 5.
(2) OJ L 441, 9.12.2021, p. 1.
(*) No constitutional requirements indicated.